WO2017000080A1 - Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用 - Google Patents

Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用 Download PDF

Info

Publication number
WO2017000080A1
WO2017000080A1 PCT/CN2015/000475 CN2015000475W WO2017000080A1 WO 2017000080 A1 WO2017000080 A1 WO 2017000080A1 CN 2015000475 W CN2015000475 W CN 2015000475W WO 2017000080 A1 WO2017000080 A1 WO 2017000080A1
Authority
WO
WIPO (PCT)
Prior art keywords
estrone
breast cancer
drug
ovarian cancer
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2015/000475
Other languages
English (en)
French (fr)
Inventor
师咏勇
宋智健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiao Tong University
Original Assignee
Shanghai Jiao Tong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiao Tong University filed Critical Shanghai Jiao Tong University
Priority to US15/740,715 priority Critical patent/US10292988B2/en
Priority to PCT/CN2015/000475 priority patent/WO2017000080A1/zh
Publication of WO2017000080A1 publication Critical patent/WO2017000080A1/zh
Anticipated expiration legal-status Critical
Priority to US16/415,543 priority patent/US10653705B2/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to the field of biotechnology, and in particular to an application of Estrone in preparing anti-ovarian cancer and/or breast cancer products.
  • Tumors are the most common and serious disease that threatens human health. Developing high-efficiency anti-tumor drugs is essential to prolong the life cycle of patients. In recent years, with the rapid development of tumor genomics and molecular pharmacology, the research and development of new anti-tumor drugs have achieved good results, but due to large investment in new drug research and development, long-term bottlenecks and other bottlenecks can not be overcome, as well as genetic variation of individual tumors. Characteristics, resulting in many traditional anti-tumor drugs are not effective, new drugs are expensive, side effects are unknown.
  • Nicardipine Promethazine, Estrone, Estrone, Sunlidac, Estrone, E tonogestrel, Levonorgestrel, Mesalazine, Indomethacin, Sulfasalazin e, Balsalazide, Irbesartan, Ibuprofen, Isoprenaline, Pentosan Polysulfate.
  • Estrone provided by the present invention for the preparation of a product for treating ovarian cancer and/or breast cancer.
  • a second object of the invention is to provide a new use of Estrone.
  • the present invention provides the use of Estrone for the preparation of a product for inhibiting proliferation of ovarian cancer cells and/or breast cancer cells.
  • a third object of the invention is to provide a new use of Estrone.
  • the present invention provides the use of Estrone for the preparation of products that reduce IC50 values of ovarian cancer cells and/or breast cancer cells.
  • Estrone in the treatment of ovarian cancer and/or breast cancer is also within the scope of the invention.
  • Estrone in inhibiting the proliferation of ovarian cancer cells and/or breast cancer cells is also within the scope of the invention.
  • Estrone as a medicament for the treatment of ovarian cancer and/or breast cancer is also within the scope of the invention.
  • Estrone as a drug for inhibiting proliferation of ovarian cancer cells and/or breast cancer cells is also within the scope of the present invention.
  • the ovarian cancer cell is SKOV-3; and the breast cancer cell is HCC1395.
  • the product is a drug or a kit.
  • a fourth object of the invention is to provide a product.
  • the product provided by the present invention has an active ingredient of Estrone; the product has at least one of the following functions:
  • the ovarian cancer cell is SKOV-3; and the breast cancer cell is HCC1395.
  • the product is a drug or a kit.
  • Figure 1 shows the distribution of drug-coated tablets in a 96-well culture plate.
  • the drug to be tested in the following examples is Estrone, and its chemical structural formula is as follows:
  • ovarian cancer cell SKOV-3 human lung cancer cell NCI-H1437 and large cell lung cancer cell NCI-H460, breast cancer cell HCC1395 in the following examples are as follows:
  • Doxorubicin positive drug from MCE, Cat.No.HY-15142
  • Example 1 CELLTITER-GLO detects Estrone against ovarian cancer and/or breast cancer
  • SKOV-3 cells were subjected to the above method to obtain SKOV-396 well cell culture plates.
  • SKOV-3 cells the complete medium was McCOY'S 5A, the life product, 16600082, and the cell density (cells/well) was 12,000.
  • step b) Take 79 ⁇ L of the 20 mM drug to be tested, which was configured in step a), into the first well of the first row of the dilution plate, and then add 54 ⁇ L of DMSO solvent to the second to the ninth well of the first row, from the first well. Take 25 ⁇ L of the solution into the second well, mix and take 25 ⁇ L of the solution from the second well to the third well, and then push it to the ninth well, ensuring that the drug is successively subjected to a 3.16 fold dilution.
  • test drug and the positive drug loading template are shown in Figure 1, where S1208: positive drug Doxorubicin, DMSO: positive control well, Cpd 1,2,3: drug to be tested, final concentration of DMSO is 0.5% (DMSO) compatibility).
  • step 1 Take the step 1 from the incubator to prepare the SKOV-396 well cell culture plate, and add 10 ⁇ l of the above b) to the SKOV-396 well cell culture plate according to the medicinal plate type arrangement of Fig. 1 (Fig. 1).
  • the cell culture medium (10X final concentration) of the concentration drug was placed in a CO 2 incubator at 37 ° C for 72 hours to obtain a 96-well drug sieve plate of SKOV-3.
  • the final concentrations and dosing conditions of the above-mentioned drugs to be tested, the positive drug Doxorubicin and the control wells in a 96-well plate are as follows:
  • the final concentration ( ⁇ M) of the drug to be tested in the 2-10 well of FIG. 1 was: 100, 31.64557, 10.01442, 3.169112, 1.002886, 0.317369, 0.100433, 0.031783, 0.010058;
  • the final concentration ( ⁇ M) of the positive drug Doxorubicin in the 2-10 well of Figure 1 was: 30, 9.493371, 3.004326, 0.950736, 0.300866, 0.095211, 0.03013, 0.009535, 0.003017;
  • S1208 wells E1-H1 and A12-D12 in a 96-well plate: 10 ⁇ l of a final concentration of 100 ⁇ M
  • Doxorubicin solution solvent is a complete medium solution containing 0.5% DMSO
  • DMSO wells A1-D1, E12-H12 and A11 -H11: 10 ⁇ l of complete medium solution containing 0.5% DMSO.
  • the complete medium for breast cancer cells HCC1395 is RPMI-1640, which is a life product, A1049101, and the cell density (cells/well) is 6000.
  • Estrone has a specific inhibitory effect on the proliferation of ovarian cancer cells and can be used as a drug for treating ovarian cancer.
  • Table 1 shows the IC50 values of different cells under the action of Estrone
  • the experiment of the present invention proves that the present invention performs tumor drug retargeting on the FDA and CFDA approved drug Estrone, and screens for different anti-tumor drugs according to different cell lines (tissue types) and mutation sites of the tumor.
  • Estrone is a new use of anti-ovarian cancer and/or breast cancer to achieve new use of old drugs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

雌酮（Estrone）在制备治疗卵巢癌和/或乳腺癌产品中的应用。雌酮在制备抑制卵巢癌细胞和/或乳腺癌细胞增殖产品中的应用。

Description

Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用 技术领域
本发明涉及生物技术领域，尤其涉及一种Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用。
背景技术
肿瘤是威胁人类健康的最常见也是最严重的一种疾病，研发高效抗肿瘤药物对延长患者的生存周期至关重要。近年来，随着肿瘤基因组学学和分子药理学的飞速发展，新型抗肿瘤药物的研发取得了不错的成果，但由于新药研发投入大，周期长等瓶颈无法克服，以及肿瘤个体遗传变异大等特征，导致许多传统抗肿瘤药物效果不加，新药价格昂贵，副作用未明。
Barabasi AL等研究者在2011年发表于《Nature Reviews Genetics》的论文中指出，基于GWAS研究结果和互作组学(interactome)策略开展的分子网络分析有望揭示复杂疾病新的药物靶点和分子标志物，并最终形成对疾病发病机制和治疗方案全新的认识。更值得注意的是，药物重定位(drug repositioning)研究发现，GWAS研究锁定的易感基因及与其有蛋白-蛋白相互作用(protein-protein interaction,PPI)的基因更容易成为药物间接的靶点，这一发现有助于解释现有药物的作用机制并指导新药的研发。2014年，Okada Y等研究者在《Nature》上发表的论文中显示GWAS研究结果整合分析得到的类风湿性关节炎的101个易感基因中有98个目前正用于治疗类风湿性关节炎药物的直接或间接靶标，而且还通过药物重定位研究，他们还发现了数十个已获批准用于其他适应症的药物也可用于治疗类风湿性关节炎。
发明公开
本研究正是通过整合癌症组学Cosmic version72数据库的癌症基因谱Cancer Gene Census以及蛋白质相互作用STRING version 10数据库和DrugBankversion4.2中FDA批准的药物数据库，获得的候选重定位药物，对肿瘤细胞系进行筛查实验，筛选出新的抗肿瘤药物。做肿瘤细胞系筛选的候选肿瘤抑制药物见如下:
Nicardipine,Promethazine,Estrone,Estrone,Sunlidac,Estrone,E tonogestrel,Levonorgestrel,Mesalazine,Indomethacin,Sulfasalazin e,Balsalazide,Irbesartan,Ibuprofen,Isoprenaline,Pentosan  Polysulfate。
本发明的一个目的是提供Estrone的新用途。
本发明提供的Estrone在制备治疗卵巢癌和/或乳腺癌产品中的应用。
本发明的第二个目的是提供Estrone的新用途。
本发明提供了Estrone在制备抑制卵巢癌细胞和/或乳腺癌细胞增殖产品中的应用。
本发明的第三个目的是提供Estrone的新用途。
本发明提供了Estrone在制备降低卵巢癌细胞和/或乳腺癌细胞IC50值产品中的应用。
Estrone在治疗卵巢癌和/或乳腺癌中的应用也是本发明保护的范围；
Estrone在抑制卵巢癌细胞和/或乳腺癌细胞增殖中的应用也是本发明保护的范围。
Estrone在作为治疗卵巢癌和/或乳腺癌药物中的应用也是本发明保护的范围；
Estrone在作为抑制卵巢癌细胞和/或乳腺癌细胞增殖药物中的应用也是本发明保护的范围。
上述应用中，所述卵巢癌细胞为SKOV-3；所述乳腺癌细胞为HCC1395。
上述应用中，所述产品为药物或试剂盒。
本发明的第四个目的是提供一种产品。
本发明提供的产品，其活性成分为Estrone；所述产品具有如下至少一种功能：
1)治疗卵巢癌和/或乳腺癌；
2)抑制卵巢癌细胞和/或乳腺癌细胞增殖；
3)降低卵巢癌细胞和/或乳腺癌细胞IC50值。
上述产品中，所述卵巢癌细胞为SKOV-3；所述乳腺癌细胞为HCC1395。
上述产品中，所述产品为药物或试剂盒。
附图说明
图1为96孔培养板药筛药物板型分布。
图2为Estrone对卵巢癌敏感；EC50＝16.4284；IC50＝21.5327；R2＝0.9875。
图3为Estrone对乳腺癌敏感；EC50＝74037.5043；IC50＝67.9510；R2＝0.9909。
实施发明的最佳方式
下述实施例中所使用的实验方法如无特殊说明，均为常规方法。
下述实施例中所用的材料、试剂等，如无特殊说明，均可从商业途径得到。
下述实施例中待测药物为Estrone，其化学结构式如下：
Figure PCTCN2015000475-appb-000001
其为drug bank产品，产品目录号为DB00655。
下面实施例中的卵巢癌细胞SKOV-3、人肺癌细胞NCI-H1437和大细胞肺癌细胞NCI-H460、乳腺癌细胞HCC1395的出处如下：
Figure PCTCN2015000475-appb-000002
下面实施例中的主要的仪器及耗材
DMSO(from Sigma,Cat.No.D4540)
96-well白色底透细胞培养板(from Corning,Cat.No.3610)
CellTiter Glo试剂盒(from Promega,Cat.No.G7573)
Doxorubicin阳性药(from MCE,Cat.No.HY-15142)
Fetal Bovine Serum(from Gibco,Cat#10099141)
100mm培养皿(from Corning,Cat#430167)
RPMI-1640medium(from Gibco,Cat#A1049101)
DMEM medium(from Gibco,Cat#11995081)
DMEM/F12medium(from Gibco,Cat#11330057)
EMEM medium(from Gibco,Cat#10370021)
Mutidrop 384细胞分液器(Thermo,Cat#5840150)
EnSpire多功能读板机(Perkin Elmer,Cat#2300-001M)
实施例1、CELLTITER-GLO检测Estrone抗卵巢癌和/或乳腺癌
一、待测孔板的制备
1、细胞铺板
a)配制各个细胞所需完全培养基。
b)实验开始前，确认标记在100mm培养皿上的药筛细胞名字，培养基以及传代时间，代次等信息，确保实验无误。
c)贴壁细胞操作参考步骤d)到i),悬浮细胞操作参考步骤j)到l)。
d)无菌操作时利用真空泵吸取细胞培养基。
e)用2ml的无菌PBS溶液润洗细胞表层，再用真空泵吸出PBS废液。
f)向培养皿轻轻加入1ml 0.25％(w/v)Trypsin-0.038％(w/v)EDTA溶液消化细胞，轻轻混匀几下，溶液覆盖住细胞表层，在倒置显微镜下观察细胞消化情况，在细胞将要脱落时终止胰酶消化作用。
g)向培养皿中加入5ml 37℃预热好的完全培养基，用移液管轻轻吹打细胞，使其从培养皿底部脱落下来。
h)将此细胞悬液转移到15ml或50ml无菌离心管中，1000rpm离心5min。
i)利用真空泵无菌操作吸出上清培养基。加入5ml 37℃预热好的完全培养基重悬细胞沉淀，轻轻吹打混匀。
j)用移液管轻轻吹打细胞，使其从培养皿底部完全脱落下来。
k)将此细胞悬液转移到15ml或50ml无菌离心管中，1000rpm离心5min。
l)利用真空泵无菌操作吸出上清培养基。加入5ml 37℃预热好的完全培养基重悬细胞沉淀，轻轻吹打混匀。
m)用细胞计数仪对细胞悬液进行计数，调整细胞悬液至合适密度接板进行细胞铺板实验。
将SKOV-3细胞按照上述方法进行，得到SKOV-396孔细胞培养板。
SKOV-3细胞，完全培养基为McCOY'S 5A，为life产品，16600082，接板密度(cells/well)为12000。
2、待测药物Estrone配制和加药(200X终浓度):
1)待测药物Estrone母板配制
a)用DMSO将待测药物Estrone稀释到20mM待用。
b)取a)步骤中配置好的20mM待测药物79μL加入稀释板第一行第一孔中，随后加入54μL的DMSO溶剂到第一行第二孔至第九孔中，从第一孔中取25μL溶液到第二孔中，混匀后从第二孔中取25μL溶液到第三孔中，依次类推到第九孔，保证药物逐次进行3.16倍倍比梯度稀释。
2)阳性药Doxorubicin(MCE,Cat.No.HY-15142)母板配制
a)用DMSO将阳性药Doxorubicin稀释到6mM待用。
b)将6mM阳性药Doxorubicin溶液加入稀释板中，DMSO溶液1:3.16倍倍比梯度稀释该待测药物。
3、药物工作板配制及加药
a)待测药物及阳性药加样模板如下图1所示，其中，S1208:阳性药Doxorubicin,DMSO:阳性对照孔,Cpd 1,2,3:待测药物,DMSO终浓度为0.5％(DMSO兼容性)。
b)向工作板中加入95μl细胞特定的完全培养基，每个药物对应9个孔，用多道排枪从待测药物和阳性药doxorubicin母板中分别依次转移5μl一系列(9个孔)倍比稀释好的溶液(10X终浓度)，得到含有不同浓度药物的细胞培养基。
c)从培养箱中取出步骤1制备SKOV-396孔细胞培养板，按图1加药板型排列方式(图1)分别向SKOV-396孔细胞培养板中加入10μl上述b)制备的含有不同浓度药物的细胞培养基(10X终浓度)，放入到CO2培养箱37℃培养72h，得到SKOV-3的96孔药筛板。
以不加任何药物的作为对照孔。
上述待测药物、阳性药Doxorubicin和对照孔在96孔板中的终浓度及加药情况如下：
待测药物在图1的2-10孔中的终浓度(μM)依次为:100、31.64557、10.01442、3.16912、1.002886、0.317369、0.100433、0.031783、0.010058；
阳性药Doxorubicin在图1的2-10孔中的终浓度(μM)依次为:30、9.493671、3.004326、0.950736、0.300866、0.095211、0.03013、0.009535、0.003017；
此外，96孔板中S1208孔(E1-H1和A12-D12):10μl终浓度100μM Doxorubicin溶液(溶剂为包含0.5％DMSO的完全培养基溶液),DMSO孔(A1-D1,E12-H12和A11-H11):10μl包含0.5％DMSO的完全培养基溶液。
二、CELLTITER-GLO荧光细胞活性检测系统检测
1、CellTiter-Glo试剂配制
a)使用前，将CellTiter-Glo试剂Buffer融化，平衡到室温使用。
b)使用前，将CellTiter-Glo试剂冻粉底物融化，平衡到室温使用。
c)取100ml平衡好的CellTiter-Glo Buffer加入到瓶装CellTiter-Glo试剂冻粉底物中，使其充分重悬形成酶/底物混合物，也就是所谓的CellTiter-Glo检测试剂。
d)轻轻混匀涡旋，并反复倒置获得均匀的溶液。一般来说，1分钟内CellTiter-Glo底物试剂就会充分溶解，分装，避光保存在-20℃备用，避免反复冻融。
2、检测
a)检测前，将上述一的3得到的SKOV-3的96孔药筛板在室温中平衡20-30分钟。
b)倒置显微镜观察每块培养板的细胞形态及死亡情况，标记出异常情况并复测一次。
c)向所有药筛孔中加入100μl上述1制备的CellTiter-Glo试剂，混匀。
d)在96孔微孔板振荡器上充分震荡混匀2分钟，使细胞完全裂解。
e)避光室温放置15分钟后进行冷光信号检测，保证信号的稳定性。
f)使用EnSpire多功能读板机570nm时读取冷光信号。
g)分析处理数据。
SKOV-3的96孔药筛板结果如图2所示。
计算IC50值，结果如表1所示。
采用同样的方法检测Estrone作用乳腺癌细胞HCC1395，细胞的IC50值，结果如表1和图3。
乳腺癌细胞HCC1395完全培养基为RPMI-1640，为life产品，A1049101，接板密度(cells/well)为6000。
采用同样的方法检测Estrone作用人肺癌细胞NCI-H1437和大细胞肺癌细胞NCI-H460，细胞的IC50值，结果如表1。
可以看出，Estrone对卵巢癌细胞增殖具有特异抑制作用，可以用来作为治疗卵巢癌的药物。
表1为不同细胞在Estrone药物作用下的IC50值
Figure PCTCN2015000475-appb-000003
工业应用
本发明的实验证明，本发明对FDA,CFDA已获批准的药物Estrone进行肿瘤药物重定位，根据肿瘤不同的细胞系(组织类型)以及突变位点对适应症不是抗肿瘤的药物进行筛选，发现Estrone抗卵巢癌和/或乳腺癌这种新用途，实现旧药新用。

Claims (9)

  1. Estrone在制备治疗卵巢癌和/或乳腺癌产品中的应用；
    或Estrone在制备抑制卵巢癌细胞和/或乳腺癌细胞增殖产品中的应用。
  2. 根据权利要求1所述的应用，其特征在于：所述卵巢癌细胞为SKOV-3；所述乳腺癌细胞为HCC1395；
    所述产品为药物或试剂盒。
  3. Estrone在治疗卵巢癌和/或乳腺癌中的应用；
    或Estrone在抑制卵巢癌细胞和/或乳腺癌细胞增殖中的应用。
  4. 根据权利要求3所述的应用，其特征在于：所述卵巢癌细胞为SKOV-3；所述乳腺癌细胞为HCC1395。
  5. Estrone在作为治疗卵巢癌和/或乳腺癌药物中的应用；
    或Estrone在作为抑制卵巢癌细胞和/或乳腺癌细胞增殖药物中的应用。
  6. 根据权利要求5所述的应用，其特征在于：所述卵巢癌细胞为SKOV-3；所述乳腺癌细胞为HCC1395。
  7. 一种产品，其活性成分为Estrone；所述产品具有如下1)和/或2)功能：
    1)治疗卵巢癌和/或乳腺癌；
    2)抑制卵巢癌细胞和/或乳腺癌细胞增殖。
  8. 根据权利要求7所述的产品，其特征在于：所述卵巢癌细胞为SKOV-3；所述乳腺癌细胞为HCC1395。
  9. 根据权利要求7所述的产品，其特征在于：所述产品为药物或试剂盒。
PCT/CN2015/000475 2015-06-30 2015-06-30 Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用 Ceased WO2017000080A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/740,715 US10292988B2 (en) 2015-06-30 2015-06-30 Applications for estrone in preparing anti-ovarian cancer and/or breast cancer products
PCT/CN2015/000475 WO2017000080A1 (zh) 2015-06-30 2015-06-30 Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用
US16/415,543 US10653705B2 (en) 2015-06-30 2019-05-17 Applications for estrone in preparing anti-ovarian cancer and/or breast cancer products

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/000475 WO2017000080A1 (zh) 2015-06-30 2015-06-30 Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US15/740,715 A-371-Of-International US10292988B2 (en) 2015-06-30 2015-06-30 Applications for estrone in preparing anti-ovarian cancer and/or breast cancer products
US16/415,543 Division US10653705B2 (en) 2015-06-30 2019-05-17 Applications for estrone in preparing anti-ovarian cancer and/or breast cancer products
US16/415,543 Continuation US10653705B2 (en) 2015-06-30 2019-05-17 Applications for estrone in preparing anti-ovarian cancer and/or breast cancer products

Publications (1)

Publication Number Publication Date
WO2017000080A1 true WO2017000080A1 (zh) 2017-01-05

Family

ID=57607380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/000475 Ceased WO2017000080A1 (zh) 2015-06-30 2015-06-30 Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用

Country Status (2)

Country Link
US (2) US10292988B2 (zh)
WO (1) WO2017000080A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1923282A (zh) * 2005-08-30 2007-03-07 孔庆忠 一种含激素类药物的抗癌缓释注射剂
CN101351188A (zh) * 2005-08-12 2009-01-21 药物技术公司 雌激素组合物和应用它们的治疗方法
CN101448501A (zh) * 2006-05-16 2009-06-03 阿斯利康(瑞典)有限公司 用于癌治疗的组合疗法
CN101896177A (zh) * 2007-12-13 2010-11-24 诺瓦提斯公司 用于治疗癌症的治疗剂的组合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1923282A (en) * 1931-11-27 1933-08-22 Int Standard Electric Corp Automatic telephone switch
US20030005433A1 (en) * 2001-03-08 2003-01-02 Janik Craig M. System and method for determining information related to broadcast content
US20030054332A1 (en) * 2001-05-10 2003-03-20 Barbosa Miguel S. Markers for evaluating estrogenic activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101351188A (zh) * 2005-08-12 2009-01-21 药物技术公司 雌激素组合物和应用它们的治疗方法
CN1923282A (zh) * 2005-08-30 2007-03-07 孔庆忠 一种含激素类药物的抗癌缓释注射剂
CN101448501A (zh) * 2006-05-16 2009-06-03 阿斯利康(瑞典)有限公司 用于癌治疗的组合疗法
CN101896177A (zh) * 2007-12-13 2010-11-24 诺瓦提斯公司 用于治疗癌症的治疗剂的组合

Also Published As

Publication number Publication date
US10292988B2 (en) 2019-05-21
US10653705B2 (en) 2020-05-19
US20180193355A1 (en) 2018-07-12
US20190374551A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
US20260007645A1 (en) Applications for nicardipine in preparing anti-lung cancer products
US20240156834A1 (en) Applications for estradiol in preparing anti-small cell lung cancer and/or ovarian cancer and/or osteosarcoma products
CN104983733A (zh) Nicardipine在制备抗肺癌产品中的应用
WO2017000081A1 (zh) Etonogestrel在制备抗前列腺癌产品中的应用
CN105012314B (zh) Etonogestrel在制备抗前列腺癌产品中的应用
CN105030792B (zh) Desogestrel在制备抗结肠癌/ER阴性的Ah受体阳性的乳腺癌产品中的应用
WO2017000080A1 (zh) Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用
WO2017000082A1 (zh) Levonorgestrel在制备抗卵巢癌产品中的应用
WO2017000084A1 (zh) Promethazine在制备抗肝癌和/或结肠癌和/或肺癌产品中的应用
WO2017000085A1 (zh) Sunlidac在制备抗肺癌产品中的应用
WO2017000078A1 (zh) Desogestrel在制备抗结肠癌/ER阴性的Ah受体阳性的乳腺癌产品中的应用
WO2017156967A1 (zh) Etonogestrel在制备抗B细胞淋巴瘤产品中的应用
CN104983735B (zh) Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用
CN105030785B (zh) Promethazine在制备抗肝癌和/或结肠癌和/或肺癌产品中的应用
CN104983734B (zh) Estradiol在制备抗小细胞肺癌和/或卵巢癌和/或骨肉瘤产品中的应用
CN105012284A (zh) Sunlidac在制备抗肺癌产品中的应用
CN104983736A (zh) Levonorgestrel在制备抗卵巢癌产品中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15896612

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15896612

Country of ref document: EP

Kind code of ref document: A1